

Development Pipeline as at 30 June 2012

Line Extensions

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing			
					US	EU	Japan	Emerging
Cardiovascular								
<i>Axanum</i>	proton pump inhibitor + low dose aspirin FDC	low dose aspirin associated peptic ulcer in high risk CV patients	III		Withdrawn	Launched	1H 2013*	Approved
<i>Brilinta/Brilique</i> EUCLID	ADP receptor antagonist	outcomes study in patients with PAD	III	3Q 2012	2016	2016	2016	2016
<i>Brilinta/Brilique</i> PEGASUS-TIMI 54	ADP receptor antagonist	outcomes study in patients with ACS	III	4Q 2010	2015	2015	2015	2015
<i>Crestor</i> [#]	statin	outcomes in subjects with elevated CRP	III		Launched	Launched		Launched
<i>Forxiga</i> TM (dapagliflozin)/ metformin FDC [#]	SGLT2 inhibitor + metformin FDC	diabetes	III	3Q 2007		3Q 2012		
<i>Forxiga</i> TM (dapagliflozin) [#]	SGLT2 inhibitor	diabetes – add on to DPP-4	III	1Q 2010		3Q 2012		
<i>Forxiga</i> TM (dapagliflozin) [#]	SGLT2 inhibitor	diabetes – add on to insulin and add-on to metformin long-term data	III	2Q 2008		3Q 2012		
<i>Forxiga</i> TM (dapagliflozin) [#]	SGLT2 inhibitor	diabetes – in patients with high CV risk - Study 18 and 19 long-term data	III	1Q 2010		2H 2013		
<i>Forxiga</i> TM (dapagliflozin) [#]	SGLT2 inhibitor	diabetes – triple therapy (dapa+met+SU)	III	1Q 2011		2H 2013		
<i>Kombiglyze XR</i> TM / <i>Komboglyze</i> TM FDC ^{#**}	DPP-4 inhibitor + metformin FDC	diabetes	III		Launched	Approved		Approved
<i>Onglyza</i> TM SAVOR-TIMI 54 [#]	DPP-4 inhibitor	outcomes study	III	2Q 2010	2016	2016		2016

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing			
					US	EU	Japan	Emerging
Gastrointestinal								
<i>Entocort</i>	glucocorticoid steroid	Crohn's disease / ulcerative colitis	III		Launched	Launched	2014	Launched
<i>Nexium</i>	proton pump inhibitor	peptic ulcer bleeding	III		Filed***	Launched		Launched
Infection								
<i>FluMist/Fluenz</i>	live, attenuated, intranasal influenza virus vaccine	influenza	III		Launched	Approved		Launched
Neuroscience								
<i>Diprivan</i> [#]	sedative and anaesthetic	conscious sedation	III			Launched	2H 2013	Launched
<i>EMLA</i> [#]	local anaesthetic	topical anaesthesia	III			Launched	Launched	Launched
Oncology								
<i>Faslodex</i>	oestrogen receptor antagonist	1 st line advanced breast cancer	III		2016	2016	2016	2016
<i>Iressa</i>	EGFR tyrosine kinase inhibitor	treatment beyond progression	III	1Q 2012		2015	2015	2015
Respiratory & Inflammation								
<i>Oxis</i>	long-acting β_2 agonist	COPD	III			Launched	Approved	
<i>Symbicort</i>	inhaled steroid/ long-acting β_2 agonist	asthma / COPD	III	4Q 2011	2014			
<i>Symbicort</i>	inhaled steroid/ long-acting β_2 agonist	COPD	III		Launched	Launched	Filed	Launched
<i>Symbicort</i>	inhaled steroid/ long-acting β_2 agonist	SMART	III			Launched	Launched	Launched

[#]Partnered product

* Nexium low-dose aspirin indications approved in 1H 2012

**Kombiglyze XRTM US; KomboglyzeTM FDC EU

***2nd CRL received in June 2011

NCEs
Phase III/Registration

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing			
					US	EU	Japan	Emerging
Cardiovascular								
<i>Brilinta/Brilique</i>	ADP receptor antagonist	arterial thrombosis	III		Launched	Launched	1H 2013	Launched
<i>ForxigaTM</i> (dapagliflozin) [#]	SGLT2 inhibitor	diabetes	III	3Q 2007	Filed*	Filed**	1H 2013	Filed
Infection								
CAZ AVI [#] (CAZ104)	beta lactamase inhibitor/ cephalosporin	serious infections	III	1Q 2012	N/A	2014	2014	2014
Q-LAIV Flu Vac ^{***}	live, attenuated, intranasal influenza virus vaccine (quadrivalent)	seasonal influenza	III		Approved	4Q 2012		
<i>Zinforo[#]</i> (ceftaroline)	extended spectrum cephalosporin with affinity to penicillin-binding proteins	pneumonia / skin infections	III	1Q 2007	N/A	Filed**		Filed
Neuroscience								
naloxegol (NKTR-118) [#]	oral peripherally-acting opioid antagonist	opioid-induced constipation	III	2Q 2011	2H 2013	2H 2013		
Oncology								
<i>Caprelsa</i>	VEGFR / EGFR tyrosine kinase inhibitor with RET kinase activity	medullary thyroid cancer	III		Launched	Launched	2014	Filed
<i>Ranmark[#]</i> (denosumab)	anti-RANKL MAb	bone disorders stemming from bone metastasis	III		N/A	N/A	Launched	N/A
Respiratory & Inflammation								
fostamatinib [#]	spleen tyrosine kinase (SYK) inhibitor	rheumatoid arthritis	III	3Q 2010	2H 2013	2H 2013		2H 2013
lesinurad	selective inhibitor of URAT1	chronic management of hyperuricaemia in patients with gout	III	4Q 2011	2014	2014	2016	2014

[#]Partnered product

*CRL received in January 2012

**Positive opinion received from CHMP in 1H 2012

***sBLA in US, MAA in EU

NCEs
Phases I and II

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing			
					US	EU	Japan	Emerging
Cardiovascular								
AZD4017	11BHS	glaucoma	II	1Q 2011				
AZD2820 [#]	melanocortin receptor type 4 (MC4r) partial agonist peptide	obesity	I	2Q 2011				
Gastrointestinal								
tralokinumab	anti-IL-13 MAb	ulcerative colitis	II	2Q 2012				
Infection								
AZD9773 [#]	anti-TNF-alpha polyclonal antibody	severe sepsis	II	1Q 2008				
CXL [#]	beta lactamase inhibitor/cephalosporin	MRSA	II	4Q 2010				
AZD5847	oxazolidinone antibacterial inhibitor	tuberculosis	I	4Q 2009				
MEDI-550	pandemic influenza virus vaccine	pandemic influenza prophylaxis	I	2Q 2006				
MEDI-557	anti-RSV MAb – extended half-life	RSV prevention in high-risk adults (COPD/CHF/ Other)	I	3Q 2007				
MEDI-559	paediatric RSV vaccine	RSV prophylaxis	I	4Q 2008				
Neuroscience								
AZD3241	myeloperoxidase (MPO) inhibitor	Parkinson's disease	II	2Q 2012				
AZD3480 [#]	alpha4/beta2 neuronal nicotinic receptor agonist	Alzheimer's disease	II	3Q 2007				
AZD5213	histamine-3 receptor antagonist	Alzheimer's disease / ADHD	II	2Q 2012				
AZD6765	NMDA receptor antagonist	major depressive disorder	II	3Q 2007				
AZD1446 [#]	alpha4/beta2 neuronal nicotinic receptor agonist	Alzheimer's disease	I	4Q 2008				
MEDI-5117	anti-IL-6 MAb	OA Pain	I	2Q 2012				

[#]Partnered product

NCEs
Phases I and II (continued)

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing			
					US	EU	Japan	Emerging
Oncology								
AZD4547	FGFR tyrosine kinase inhibitor	solid tumours	II	4Q 2011				
AZD8931	erbB kinase inhibitor	breast cancer chemo. combi./solid tumours	II	2Q 2010				
fostamatinib [#]	spleen tyrosine kinase (SYK) inhibitor	haematological malignancies	II	1Q 2012				
MEDI-551 [#]	anti-CD19 MAb	haematological malignancies	II	1Q 2012				
MEDI-573 [#]	anti-IGF MAb	solid tumours	II	2Q 2012				
MEDI-575 [#]	anti-PDGFR-alpha MAb	NSCLC / glioblastoma	II	4Q 2010				
olaparib	PARP inhibitor	gBRCA ovarian cancer	II	1Q 2012				
selumetinib [#] (AZD6244) (ARRY-142886)	MEK inhibitor	solid tumours	II	4Q 2006				
tremelimumab	anti-CTLA4 MAb	solid tumours	II	3Q 2004				
AZD1208	PIM kinase inhibitor	haematological malignancies	I	1Q 2012				
AZD1480	JAK1, 2 inhibitor	solid tumours	I	2Q 2009				
AZD2014	TOR kinase inhibitor	solid tumours	I	1Q 2010				
AZD3514	androgen receptor down-regulator	prostate cancer	I	3Q 2010				
AZD5363 [#]	AKT inhibitor	solid tumours	I	4Q 2010				
AZD8330 [#] (ARRY 424704)	MEK inhibitor	solid tumours	I	1Q 2007				
MEDI-0639	anti-DLL-4 MAb	solid tumours	I	2Q 2012				
MEDI-3617 [#]	anti-ANG-2 MAb	solid tumours	I	4Q 2010				
MEDI-565 [#]	anti-CEA BiTE	solid tumours	I	1Q 2011				
MEDI-6469 [#]	murine anti-OX40 MAb	solid tumours	I	1Q 2006				
moxetumomab pasudotox [#]	anti-CD22 recombinant immunotoxin	haematological malignancies	I	2Q 2007				
selumetinib (AZD6244) (ARRY-142886) /MK2206 [#]	MEK/AKT inhibitor	solid tumours	I	4Q 2009				
volitinib [#]	MET inhibitor	solid tumours	I	1Q 2012				

[#]Partnered product

NCEs
Phases I and II (continued)

Compound	Mechanism	Area Under Investigation	Phase	Date Commenced Phase	Estimated Filing			
					US	EU	Japan	Emerging
Respiratory & Inflammation								
AZD2115	MABA	COPD	II	2Q 2012				
AZD5069	CXCR2	asthma	II	4Q 2010				
AZD5423	inhaled SGRM	COPD	II	4Q 2010				
AZD8683	muscarinic antagonist	COPD	II	4Q 2010				
benralizumab [#]	anti-IL-5R MAb	asthma / COPD	II	4Q 2008				
brodalumab [#]	anti-IL-17R MAb	psoriasis / psoriatic arthritis / asthma	II	4Q 2009				
mavrilimumab [#]	anti-GM-CSFR MAb	rheumatoid arthritis	II	1Q 2010				
MEDI-546 [#]	anti-IFN-alphaR MAb	SLE	II	1Q 2012				
MEDI-8968 [#]	anti-IL-1R MAb	COPD	II	4Q 2011				
sifalimumab [#]	anti-IFN-alpha MAb	SLE	II	3Q 2008				
tralokinumab	anti-IL-13 MAb	asthma	II	1Q 2008				
AZD8848	inhaled TLR7	asthma	I	2Q 2012				
MEDI-2070 [#]	anti-IL-23 MAb	Crohn's disease	I	2Q 2010				
MEDI-4212	anti-IgE MAb	asthma	I	1Q 2012				
MEDI-551 [#]	anti-CD19 MAb	scleroderma	I	2Q 2010				
MEDI-570 [#]	anti-ICOS MAb	SLE	I	2Q 2010				
MEDI-5872 [#]	anti-B7RP1 MAb	SLE	I	4Q 2008				
MEDI-7183 [#]	anti-A4b7 MAb	Crohn's disease / ulcerative colitis	I	3Q 2010				
MEDI-7814	anti-C5/C5a MAb	COPD	I	1Q 2012				
MEDI-9929 [#]	anti-TSLP MAb	asthma	I	4Q 2008				
RDEA3170	selective inhibitor of URAT1	chronic management of hyperuricaemia in patients with gout	I	3Q 2011				

[#]Partnered product

Development Pipeline - Discontinued Projects between 31 December 2011 and 30 June 2012

Cardiovascular

NCE/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NCE	AZD2927	Safety/Efficacy	atrial fibrillation

Neuroscience

NCE/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NCE	AZD2423	Safety/Efficacy	chronic neuropathic pain
NCE	AZD3839	Safety/Efficacy	Alzheimer's disease
NCE	MEDI-578	Regulatory	OA pain
NCE	TC-5214	Safety/Efficacy	major depressive disorder (monotherapy)
NCE	TC-5214	Safety/Efficacy	major depressive disorder (adjunct)

Infection

NCE/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NCE	AZD5099	Safety/Efficacy	serious infections
NCE	MEDI-534	Safety/Efficacy	RSV/PIV prophylaxis

Respiratory & Inflammation

NCE/Line Extension	Compound	Reason for Discontinuation	Area Under Investigation
NCE	AZD1981	Safety/Efficacy	asthma/COPD
NCE	AZD2423	Safety/Efficacy	COPD

Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Submission dates shown for assets in Phase III and beyond.